FDA Grants Fast Track Status to New Skin Condition Treatment

Palvella Therapeutics (PVLA) receives FDA Fast Track designation for QTORIN rapamycin gel to treat angiokeratomas, a rare skin condition with no approved therapies affecting 50,000+ US patients.